Discovery Partners International Inc.

Biotech IPO pricing is fraught with more uncertainty than ever before, say some private investors and executives. It's worth seriously considering the alternatives. By Christopher Morrison During the

Through a reverse merger with Discovery Partners International Inc. , oncology discovery and development play Infinity Pharmaceuticals Inc. will access the public market and Discovery's roughly

VC firm Oxford Bioscience's deal with Evotec gives its portfolio companies discounted access to the German biotech's screening and chemistry services—but with no obligation. Nothing is better at bring

A diverse library of chemical compounds for initial lead generation, augmented by intelligently chosen structure-specific sublibraries for iterative screening, may hold the key to improved productivit